Hjem › Multipelt myelom › Nebraska › Lincoln
Kliniske studier for Multipelt myelom i Lincoln, NE
3 studier for Multipelt myelom søker deltakere på steder i og rundt Lincoln (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
RekruttererFase 3
- NHO Revive Research Institute, LLC, Lincoln
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
RekruttererFase 3
- Bryan Medical Center, Lincoln
- NHO Revive Research Institute, LLC, Lincoln
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
RekruttererFase 1
- NHO Revive Research Institute, LLC /ID# 267869, Lincoln
Multipelt myelom-studier i andre byer
- New York City, NY60 studier
- Boston, MA42 studier
- Atlanta, GA41 studier
- Houston, TX38 studier
- Durham, NC37 studier
- Nashville, TN32 studier
- Denver, CO27 studier
- Rochester, MN24 studier
- St. Louis, MO24 studier
- Columbus, OH24 studier
- Baldwin Park, CA23 studier
- Chicago, IL22 studier
Andre studier i Lincoln
- Ikke-småcellet lungekreft16 studier
- Hjertesvikt8 studier
- Lungekreft7 studier
- Koronararteriesykdom5 studier
- Brystkreft4 studier
- Fedme4 studier
- Schizofreni4 studier
- Kolorektal kreft4 studier
- Melanom3 studier
- Amyotrofisk lateralsklerose3 studier
- Kreft (alle typer)3 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.